<DOC>
	<DOCNO>NCT02822638</DOCNO>
	<brief_summary>Ischemic heart disease lead cause mortality industrialized country . ST elevate acute myocardial infarction one frequent deadly manifestation . In last 20 year , STEMI mortality reduce 50 % advent timely reperfusion ( primary percutaneous intervention ) significant progression pharmacologic intervention . However , death heart failure incidence STEMI remain elevated : 20 % one year . Also , therapeutic management follow international guideline standardize toward `` one-size fit '' therapeutic management . In order continue improve myocardial infarction outcome , need good understand individualize therapeutic target myocardial reperfusion injury , post reperfusion inflammation , adverse leave ventricular ( LV ) remodel … . This knowledge allow u propose new therapeutic strategy long run strive towards personalize medicine . The aim objective cohort STEMI patient identify new biological marker injury prognosis .</brief_summary>
	<brief_title>Cohort STEMI Patients</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Age &gt; 18 year Diagnosis STEMI define ST segment elevation ≥ 0.2 mV 2 contiguous lead 12lead ECG . Primary PCI within 12 hour symptoms onset . Diagnosis STEMI confirm angiography Refusal participate study sign consent Inability give information subject study Lack medical social coverage Deprivation civil right</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Myocardial infarction</keyword>
	<keyword>biomarkers</keyword>
	<keyword>STEMI</keyword>
</DOC>